My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novartis AG Common Stock (NY:NVS)

137.87 -0.85 (-0.61%)

Official Closing Price Updated: 7:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

53 54 Next >

R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

May 02, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

Via FinancialNewsMedia

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

Is This Big Pharma Stock a Buy for Dividend Investors? ↗

April 27, 2023

The Swiss pharmaceutical giant possesses a tremendous product pipeline.

Via The Motley Fool

Why Novartis Stock Is Trading Higher Today ↗

April 25, 2023

Via Benzinga

Earnings Preview: Novartis ↗

April 24, 2023

Via Benzinga

Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels ↗

April 26, 2023

Novartis AG (NYSE: NVS) released detailed

Via Benzinga

After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines ↗

April 25, 2023

In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam.

Via Benzinga

Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise ↗

April 25, 2023

Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations.

Via Investor's Business Daily

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

Why Legend Biotech Stock Is Having Its Best Month Yet

April 25, 2023

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

Via MarketBeat

New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know ↗

April 18, 2023

Via Benzinga

Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 13, 2023

Via Benzinga

Novartis AG (NYSE: NVS) Records 52-Week High Thursday Morning

April 06, 2023

Via Investor Brand Network

Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment ↗

April 20, 2023

Via Benzinga

Why Shares of Legend Biotech Jumped Wednesday ↗

April 19, 2023

A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.

Via The Motley Fool

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

April 18, 2023

Via Investor Brand Network

2 Best Biotech Stocks to Buy for the Long Haul ↗

April 17, 2023

These two are among the largest pharma companies in the world.

Via The Motley Fool

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late ↗

April 16, 2023

You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.

Via InvestorPlace

Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says ↗

April 13, 2023

Via Benzinga

Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer? ↗

April 13, 2023

In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...

Via Benzinga

Trillions In Biotech Stock Gains Trace Back To This Financier ↗

April 13, 2023

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Via Investor's Business Daily

Epic Growth Story Predicted for Pharmaceutical Drug Delivery Market's Future: Johnson & Johnson, Novartis International, Merck

April 12, 2023

Stay up-to-date with Pharmaceutical Drug Delivery Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher

April 12, 2023

Tilray Brands moves lower on mixed results, but the bottom may be in, with positive FCF expected this quarter. The long-term catalyst is US legalization.

Via MarketBeat

Topics Cannabis

Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move ↗

April 10, 2023

Via Benzinga

Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗

April 10, 2023

Shares are closing in on a buy point out of a consolidation.

Via Investor's Business Daily

Pediatric Drugs Market Giants Spending Is Going to Boom : Pfizer, Bayer, Abbott Laboratories, Merck

April 10, 2023

NJ New Jersey, USA -- (SBWIRE) -- 04/10/2023 -- Latest Study on Industrial Growth of Pediatric Drugs Market 2022-2027. A detailed study accumulated to offer Latest insights about acute features of the...

Via SBWire

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗

April 10, 2023

The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Via Benzinga

Novartis Shares Leap On Positive Clinical Trial Data

April 10, 2023

Swiss pharmaceutical giant Novartis leaped 5.11% in the past week following news that its Kisqali breast-cancer treatment cut the probability of relapse.

Via MarketBeat

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative' ↗

April 07, 2023

Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.

Via Benzinga

7 Very Undervalued Penny Stocks to Buy in April 2023 ↗

April 06, 2023

Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.

Via InvestorPlace

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.